Abstract
Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.
| Original language | English |
|---|---|
| Pages (from-to) | 177-186 |
| Number of pages | 10 |
| Journal | Expert Review of Gastroenterology and Hepatology |
| Volume | 10 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2016 Feb 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. / Lee, Hye Won; Park, Junyong; Ahn, SangHoon.
In: Expert Review of Gastroenterology and Hepatology, Vol. 10, No. 2, 01.02.2016, p. 177-186.Research output: Contribution to journal › Article
TY - JOUR
T1 - An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults
AU - Lee, Hye Won
AU - Park, Junyong
AU - Ahn, SangHoon
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.
AB - Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.
UR - http://www.scopus.com/inward/record.url?scp=84956727898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956727898&partnerID=8YFLogxK
U2 - 10.1586/17474124.2016.1125781
DO - 10.1586/17474124.2016.1125781
M3 - Article
C2 - 26610256
AN - SCOPUS:84956727898
VL - 10
SP - 177
EP - 186
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
IS - 2
ER -